Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Stephanie Le Breton"'
Autor:
Jens Jordan, Sam W. Boye, Stephanie Le Breton, Deborah L. Keefe, Stefan Engeli, Margaret Forney Prescott
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 3 (2012)
Background : Even though patients with class 3 obesity (body mass index ≥ 40 kg/m 2 ) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospect
Externí odkaz:
https://doaj.org/article/9182fc60da29427cb10d2ae8717e9d83
Publikováno v:
Hypertension Research. 33:62-66
This 12-week, multicenter, open-label study assessed the efficacy, pharmacokinetics and safety of a once-daily aliskiren in Japanese hypertensive patients with renal dysfunction. Patients (n=40, aged 20-80 years) with mean sitting diastolic blood pre
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7ccbdcda9fa79ffe44b6f4564cca33bf
https://doi.org/10.1038/hr.2009.175
https://doi.org/10.1038/hr.2009.175
Autor:
Stephanie Le Breton, Peter Baumgart, Andrzej Tykarski, Bernard Reimund, Philippe Ferber, Jaakko Tuomilehto
Publikováno v:
Blood Pressure. 17:15-23
To investigate the efficacy and tolerability of valsartan (Val) 320 mg once daily (o.d.), Val/hydrochlorothiazide (HCTZ) 320/12.5 mg o.d. and Val/HCTZ 320/25 mg o.d. in patients with hypertension not adequately controlled by Val monotherapy.This doub
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2543ccf9879d26525705555d026961a
https://doi.org/10.1080/08038020701832716
https://doi.org/10.1080/08038020701832716
Publikováno v:
Hypertension. 49:1047-1055
Current guidelines from the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recommend first-line treatment with a thiazide diuretic but do not provide specific guidance for obese patients. The renin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ac1bce093f8937d71f89f33dbd33bac
https://doi.org/10.1161/hypertensionaha.106.084301
https://doi.org/10.1161/hypertensionaha.106.084301
Autor:
Margaret F. Prescott, Stefan Engeli, Sam W. Boye, Stephanie Le Breton, Jens Jordan, Deborah L. Keefe
Publikováno v:
Therapeutic Advances in Endocrinology and Metabolism, Vol 3 (2012)
Background: Even though patients with class 3 obesity (body mass index ≥ 40 kg/m2) are prone to arterial hypertension and respond less to antihypertensive drugs, they are not considered in hypertension treatment guidelines and data from prospective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44990e1118e6ad36c37c7456e1214c5d
https://doaj.org/article/9182fc60da29427cb10d2ae8717e9d83
https://doaj.org/article/9182fc60da29427cb10d2ae8717e9d83
Publikováno v:
Journal of clinical pharmacology. 52(12)
This randomized, double-blind, placebo-controlled study assessed the efficacy, safety, and tolerability of aliskiren 75, 150, and 300 mg to clarify the dose-response relationship and characterize the optimum aliskiren dose when given with a light mea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc55322f0de559efd6270f41cc3f1c79
https://pubmed.ncbi.nlm.nih.gov/22174431
https://pubmed.ncbi.nlm.nih.gov/22174431